Business / Finance

RSS

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

Vomaris signs exclusive global commercial partnership with Metrex for Procellera Antimicrobial Wound Dressings

Vomaris Innovations, Inc. announced today that it has entered into an exclusive global commercial partnership for its microcurrent generating wound care products, Procellera Antimicrobial Wound Dressings, for the Long Term Care market with Metrex, a professional consumables brand within Kavo Kerr Group, which is a member of the Danaher Corporation.

15 Sep 2015

NanoString announces key initiatives to expand market for nCounter Analysis System, related product portfolio

At a meeting with analysts and investors today, members of the senior management team of NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, plan to unveil the company’s strategic roadmap to drive continued growth and expand the market for its nCounter Analysis System and the related product portfolio.

From NanoString Technologies 14 Sep 2015

HealthSouth to offer $300M aggregate principal amount of senior notes through private placement

HealthSouth Corporation today announced it intends to offer through a private placement, subject to market and other conditions, $300 million aggregate principal amount of senior notes due 2025.

11 Sep 2015

ULURU signs definitive agreement to sell common stock to European investors

ULURU Inc., a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced the signing of a definitive agreement to sell an aggregate of 4,079,539 shares of its common stock at a price per share of $0.38 to a group of European investors, which is expected to result in gross proceeds of $1,550,225.

11 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

Vestagen Technical Textiles completes $3.3 million convertible note bridge financing

Vestagen Technical Textiles, Inc., today announced that it has completed a $3.3 million convertible note bridge financing. Advent Life Sciences and HealthQuest Capital led the financing, and other existing Vestagen investors also participated.

9 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.

8 Sep 2015

Impax Laboratories receives FDA notice regarding Hayward manufacturing facility

Impax Laboratories, Inc. today announced that it received written notice from the United States Food and Drug Administration verifying that the Company has successfully addressed all items raised by the FDA in the May 2011 Warning Letter relating to its Hayward, California manufacturing facility.

8 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

4 Sep 2015

Cipla enters into definitive agreements to acquire two US-based companies

Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.

4 Sep 2015

Publicis Healthcare purchases Tardis Medical

Publicis Healthcare, a part of Publicis Groupe, announced today that it has acquired Tardis Medical. Tardis Medical is a highly respected clinical and medical affairs outsourcing organization and consultancy business. The agency will be aligned with Publicis Touchpoint Solutions, part of PHCG, Inc—a leading provider of customized, omnichannel healthcare sales, service, and clinical teams.

3 Sep 2015

Acal BFi inks channel partner agreement in Europe with SynQor

Acal BFi, European leader in advanced technology solutions, have signed a channel partner agreement in Europe with SynQor to include UK, Ireland, Denmark, Sweden, Norway, Finland, Belgium, Netherlands, Luxemburg and Italy.

3 Sep 2015

Lannett enters into definitive agreement to purchase KU for $1.23 billion

Lannett Company, Inc. today announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments.

3 Sep 2015

Prime Healthcare Services acquires St. Joseph Mercy Port Huron

Prime Healthcare Services, the fastest growing hospital system in the nation, announced today that it has completed the acquisition of St. Joseph Mercy Port Huron. As a result, St. Joseph Mercy Port Huron will now be known as Lake Huron Medical Center.

3 Sep 2015

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc, have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease.

2 Sep 2015

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million.

2 Sep 2015

Voalte secures $17 million in Series D funding

Voalte, the leader in healthcare communication technology, today announced a new capital infusion of $17 million by Ascension Ventures, Cerner Capital, Inc., an affiliate of Cerner Corporation, and Bedford Funding. Series D funding closed on July 27, 2015, bringing the total capital Voalte has raised to nearly $60 million in three years.

2 Sep 2015

Business / Finance

Immune Pharmaceuticals’ CEO establishes stock trading plan

Vomaris signs exclusive global commercial partnership with Metrex for Procellera Antimicrobial Wound Dressings

NanoString announces key initiatives to expand market for nCounter Analysis System, related product portfolio

HealthSouth to offer $300M aggregate principal amount of senior notes through private placement

ULURU signs definitive agreement to sell common stock to European investors

CureVac announces official launch of U.S. operations in Cambridge, MA

Vestagen Technical Textiles completes $3.3 million convertible note bridge financing

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

Impax Laboratories receives FDA notice regarding Hayward manufacturing facility

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Cipla enters into definitive agreements to acquire two US-based companies

Publicis Healthcare purchases Tardis Medical

Acal BFi inks channel partner agreement in Europe with SynQor

Lannett enters into definitive agreement to purchase KU for $1.23 billion

Prime Healthcare Services acquires St. Joseph Mercy Port Huron

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Ascletis completes US$35 million (RMB 220 million) financing

Voalte secures $17 million in Series D funding

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Latest News